Sung H,Ferlay J,Siegel RL,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin[J]. 2021，71(3):209-249.

Chen W,Zheng R,Baade PD,et al. Cancer statistics in China, 2015. CA Cancer J Clin[J]. 2016,66(2):115-32.

Nasim F,Sabath BF,Eapen GA. Lung Cancer. Med Clin North Am[J]. 2019,103(3):463-473. DOI:10.1016/j.mcna.2018.12.006http://dx.doi.org/10.1016/j.mcna.2018.12.006.

Daaboul N,Nicholas G,Laurie SA. Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer:an evidence-based overview[J]. Current Oncology,2018,25(1):77-85.

National Comprehensive Cancer Network. NCCN clinical practice guidelines:non-small cell lung cancer(version3.2019)[EB/OL].(2019-01-18)[2021-11-15].https://www.nccn.org/professionals/physician gls/pdf/nscl.pdfhttps://www.nccn.org/professionals/physiciangls/pdf/nscl.pdf.

Soon YY,Stockler MR,Askie LM,et al. Duration of chemotherapy for advanced non-small-cell lung cancer:a systematic review and meta-analysis of randomized trials[J]. J Clin Oncol,2009,27(20):3277-3283.

陈芋屹,韩燕,关鼎鲲,等. 杨国旺病证结合治疗肺部肿瘤及相关病症经验[J]. 北京中医药,2019,38(10):1009-1011.

李可. 攻癌夺命汤治验录[N]. 中国中医药报,2006-08-07(006).

刘明. 用攻癌夺命汤治愈晚期宫颈癌的体会[J]. 内蒙古中医药,2011,30(9):54.

许筱梅,袁房均,张有顺,等. 攻癌夺命组方对肝癌细胞系HepG2的杀伤作用研究[J]. 中国实验方剂学杂志,2010,16(13):145-148.

连雅君,王庆国,王雪茜,等. 海藻-甘草配伍禁忌理论由来探讨[J]. 中华中医药杂志,2020,35(10):4934-4936.

曹琰. 基于“十八反”的中药配伍禁忌理论基础研究[D]. 南京:南京中医药大学,2014.

赵晶,周利婷,魏玉辉,等. 海藻甘草配伍后水提取物对大鼠肝细胞膜Ntcp的影响[J]. 中南药学,2014,12(7):619-622.